Dengue cities sprayed insecticide for decades; this team released more mosquitoes instead

Dengue is among the fastest-spreading mosquito-borne viruses on earth, concentrated in cities and carried by Aedes aegypti — a mosquito perfectly adapted to human neighbourhoods. The standard arsenal was insecticide spraying and clearing standing water, both losing ground to resistance, labour cost and the vector's adaptability. A modelling study cited by the trial team estimated 7.8 million symptomatic infections in Indonesia alone in 2015.

Scott O'Neill's lab (then at Monash University, later the World Mosquito Program) had found that wMel, a common bacterium carried by many insects, does something remarkable inside Aedes aegypti: it reduces the mosquito's capacity to transmit dengue and related viruses. Wolbachia also spreads by itself — infected mothers pass it to nearly all their offspring, and it gives carriers a reproductive edge over uninfected rivals. The question was whether releasing infected mosquitoes could convert a wild city population into one that could not transmit.

Released Wolbachia-carrying mosquitoes that block dengue and spread the bacterium through the wild population, turning each release into self-propagating infrastructure.

Wolbachia passes from infected mothers to nearly all their offspring, and it gives carriers a reproductive edge — so the bacterium invades the wild population on its own momentum.

Once established, every generation of mosquitoes is born less able to transmit dengue; the intervention maintains itself where insecticides decay and sterile-male releases die out in a generation.

The cost curve inverts: you pay once for rearing and release, and the city's own mosquitoes do the rest of the deployment.

When each instance of a harm reproduces itself — a pest, a fraud pattern, a bad habit spreading through an organisation — chasing instances loses; convert the carrier so it propagates the fix instead,

Treated Yogyakarta neighbourhoods saw dengue fall ~73% vs controls, the randomised trial found 77% efficacy, and Niterói repeated 69%.